GSK plc (GSK)GSKGSK plc

Financials

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	44.32B	11.15B	10.08B	11.60B	11.49B	10.97B	9.71B	10.16B	10.72B
Cost of Goods Sold	12.09B	3.00B	2.48B	3.58B	3.04B	2.97B	2.50B	3.20B	3.21B
Gross Profit	32.23B	8.14B	7.61B	8.02B	8.46B	7.99B	7.21B	6.95B	7.51B
Gross Profit Margin	72.7%	73.1%	75.4%	69.2%	73.6%	72.9%	74.2%	68.5%	70.1%
Total Operating Expenses	23.04B	7.51B	4.57B	5.99B	4.97B	5.22B	4.34B	6.08B	7.26B
Research & Development	12.26B	4.60B	2.24B	3.16B	2.27B	2.78B	1.89B	2.54B	1.95B
Selling, General & Administrative	12.28B	2.92B	2.80B	3.55B	3.01B	2.94B	2.67B	3.33B	5.08B
Operating Income (EBIT)	9.18B	637.71M	3.03B	2.03B	3.49B	2.78B	2.86B	870.79M	252.76M
Operating Margin	20.7%	5.7%	30.1%	17.5%	30.3%	25.3%	29.5%	8.6%	2.4%
Income Before Tax (EBT)	7.88B	469.33M	2.83B	1.28B	3.30B	2.59B	2.72B	704.39M	85.59M
Interest Income	140.93M	76.90M	29.08M	N/A	34.96M	68.66M	69.75M	-63.81M	42.80M
Interest Expense	920.67M	241.30M	220.73M	234.12M	224.52M	252.65M	209.25M	180.16M	208.63M
Other Income/Expense	-1.30B	-168.38M	-196.94M	-748.12M	-184.19M	-186.74M	-139.50M	-166.40M	-167.17M
Net Income	6.43B	576.72M	2.30B	855.76M	2.71B	1.98B	2.10B	517.97M	-77.57M
Income Tax Expense	858.82M	-263.83M	403.13M	300.06M	419.47M	330.92M	434.01M	77.57M	-1.34M
Net Profit Margin	14.5%	5.2%	22.8%	7.4%	23.6%	18.1%	21.6%	5.1%	-0.7%
EBITDA	14.87B	3.67B	3.64B	3.08B	4.48B	4.37B	3.93B	1.39B	1.52B
EBITDA Margin	33.6%	33.0%	36.1%	26.6%	39.0%	39.8%	40.4%	13.7%	14.2%
Depreciation & Amortization	5.69B	3.04B	611.97M	1.05B	992.20M	1.59B	1.06B	515.47M	1.27B
EPS Basic	3.20	0.29	1.14	0.43	1.34	0.99	1.03	0.25	-0.04
EPS Diluted	3.16	0.29	1.14	0.42	1.32	0.96	1.01	0.25	-0.04
Shares Outstanding	2.01B	2.01B	2.01B	2.01B	2.02B	2.03B	2.04B	2.04B	2.04B
Diluted Shares Outstanding	2.03B	2.03B	2.04B	2.04B	2.05B	2.06B	2.07B	2.07B	2.04B

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	43.95B	39.26B	38.59B	35.44B	33.42B	33.26B	44.72B	39.26B
Cost of Goods Sold	12.13B	11.32B	10.90B	11.55B	11.05B	10.83B	15.72B	13.05B
Gross Profit	31.82B	27.94B	27.69B	23.89B	22.37B	22.43B	29.01B	26.22B
Gross Profit Margin	72.4%	71.2%	71.8%	67.4%	66.9%	67.4%	64.9%	66.8%
Total Operating Expenses	20.60B	22.90B	19.11B	16.12B	16.48B	14.27B	19.78B	19.23B
Research & Development	10.13B	8.01B	7.92B	6.63B	6.79B	6.55B	6.05B	4.96B
Selling, General & Administrative	12.23B	13.78B	11.94B	10.12B	9.57B	10.16B	15.11B	12.63B
Operating Income (EBIT)	11.22B	5.03B	8.58B	7.77B	5.90B	8.16B	9.22B	6.98B
Operating Margin	25.5%	12.8%	22.2%	21.9%	17.6%	24.6%	20.6%	17.8%
Income Before Tax (EBT)	9.96B	4.35B	7.72B	6.80B	4.87B	7.06B	8.24B	6.11B
Interest Income	75.35M	84.32M	50.89M	77.67M	37.89M	60.09M	129.85M	99.15M
Interest Expense	924.39M	822.72M	986.06M	1.03B	1.06B	1.22B	1.21B	947.33M
Other Income/Expense	-1.26B	-680.61M	-866.46M	-972.90M	-1.03B	-1.10B	-980.51M	-870.08M
Net Income	7.69B	3.22B	6.27B	18.08B	5.93B	7.85B	6.15B	4.62B
Income Tax Expense	1.50B	658.09M	961.88M	854.46M	112.32M	91.50M	1.26B	960.53M
Net Profit Margin	17.5%	8.2%	16.2%	51.0%	17.8%	23.6%	13.8%	11.8%
EBITDA	14.33B	8.22B	11.50B	10.37B	8.77B	10.96B	12.03B	9.35B
EBITDA Margin	32.6%	20.9%	29.8%	29.3%	26.2%	33.0%	26.9%	23.8%
Depreciation & Amortization	3.11B	3.19B	2.92B	2.59B	2.87B	2.80B	2.81B	2.36B
EPS Basic	3.79	1.58	3.10	8.99	3.71	3.93	3.10	2.34
EPS Diluted	3.74	1.55	3.05	8.85	3.65	3.91	3.07	2.32
Shares Outstanding	2.03B	2.04B	2.03B	2.01B	1.60B	1.99B	1.98B	1.97B
Diluted Shares Outstanding	2.06B	2.07B	2.06B	2.04B	1.62B	2.02B	2.01B	1.99B

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About GSK plc

GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.

London, GL

66,841 employees

www.gsk.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Luke Victor Miels

View full financials